UK-432,097
 | |
| Names | |
|---|---|
| IUPAC name
6-(2,2-diphenylethylamino)-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9H-purine-2-carboxamide | |
| Identifiers | |
| Abbreviations | UK-432,097 |
380221-63-6  | |
| ChemSpider | 8009243  |
| |
| Jmol-3D images | Image Image |
| PubChem | 9833519 |
| |
| Properties | |
| Molecular formula |
C40H47N11O6 |
| Molar mass | 777.87 g·mol−1 |
| Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| verify (what is: /?) | |
| Infobox references | |
UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor.[1] It was discontinued from clinical trials following poor efficacy results,[2] but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.[3]
References
- ↑ Russo, Cristina; Arcidiacono, Giuseppe; Polosa, Riccardo (2006). "Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma". Fundamental and Clinical Pharmacology 20 (1): 9–19. doi:10.1111/j.1472-8206.2005.00388.x. PMID 16448391.
- ↑ Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
- ↑ Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (March 2011). "Structure of an Agonist-Bound Human A2A Adenosine Receptor". Science 332 (6027): 322–7. doi:10.1126/science.1202793. PMC 3086811. PMID 21393508.